The
European Research Council has a number of Implementing Arrangements (IAs). These arrangements provide opportunities in Europe for early-career scientists supported by non-European funding agencies to temporarily join a research team run by an ERC grantee. The purpose of the arrangements is to encourage, develop and facilitate such opportunities.
Currently the following arrangements are in place:
- United States, signed 13 Jul 2012, with the National Science Foundation (NSF)
Read more: agreement, press release
- Korea, signed 8 Nov 2013, with the Ministry of Science, ICT and Future Planning
Read more: agreement, press highlight - Argentina, signed 13 Mar 2015, with the Ministry of Science, Technology and Productive Innovation
Read more: agreement EN, press highlight
- Japan, signed 29 May 2015 with the Society for the Promotion of Science (JSPS)
Read more: agreement EN, press release
- China, signed 29 Jun 2015, with the National Natural Science Foundation (NSFC)
Read more: agreement EN, press highlight
- South Africa, signed 26 Oct 2015, with the National Research Foundation (NRF)
Read more: agreement EN - Mexico, signed 12 Nov 2015, with the Mexican National Council of Science and Technology (Conacyt)
Read more: agreement EN, press highlight
New similar arrangements from various geographically areas are being negotiated. It is expected to have them signed in 2015 and 2016.











Join the 17th Annual Postgraduate Research Conference – Wednesday 3 December 2025
BU Festival of Social Sciences invite at RNLI
MaGPIE Presents at UK Parliament: From Mass Graves to Courtroom
Festival of Social Science: Introducing drowning prevention in Bangladesh
BU PhD student attending HIV conference on scholarship
ECR Funding Open Call: Research Culture & Community Grant – Apply Now
MSCA Postdoctoral Fellowships 2025 Call
ERC Advanced Grant 2025 Webinar
Horizon Europe Work Programme 2025 Published
Horizon Europe 2025 Work Programme pre-Published
Update on UKRO services
European research project exploring use of ‘virtual twins’ to better manage metabolic associated fatty liver disease